LDS/Medical Tests/Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements, FISH, Tissue

Anaplastic Lymphoma Kinase (ALK) Gene Rearrangements, FISH, Tissue

Lung cancer is one of the most prevalent cancers but responds poorly to traditional chemotherapy. Mutation status of lung tumors offers what has become critical information used to assign therapy, especially newer agents like tyrosine kinase inhibitors (TKIs), that elicit a better response.

The anaplastic large cell lymphoma kinase (ALK) gene was initially discovered in 1994 via the cloning of the t(2;5)(p23;q35) translocation found in a subset of anaplastic large-cell lymphomas. Its association with NSCLC was reported in 2007 when a small inversion within chromosome 2p that juxtaposes the 5’ end of the echinoderm microtubule-associated protein-like 4 (EML4) gene with the 3’ end of the ALK gene, producing a novel fusion oncogene EML4-ALK in NSCLC cells.

The fusion of the EML4 gene with the ALK gene results from an inversion of chromosome band 2p23. ALK rearrangements are associated with characteristic clinicopathologic findings. These include adenocarcinoma histology (found in 4-7% of cancers with acinar or signet ring type) and a higher frequency in young male non-smokers or light smokers. Lung cancers harboring ALK gene rearrangements have shown to be resistant to drugs inhibiting epidermal growth factor receptor (EGFR) tyrosine kinase activity, but may be highly sensitive to ALK inhibitors, like Xalkori (crizotinib). This drug acts as an inhibitor by blocking kinase activity produced by the ALK gene translocation.

Treatment with Xalkori has been shown to inhibit tumor progression and increase survival in patients with these types of lung cancer. Therefore, identifying lung cancer harboring this gene translocation is important for therapeutic disease management. ALK gene rearrangement does not occur in tumors with EGFR or KRAS mutations, and vice versa.

  • Determine therapeutic strategies for anaplastic large-cell lymphoma carrying ALK gene rearrangement
  • Determine therapeutic strategies for non-small cell lung cancer (NSCLC) carrying ALK gene rearrangement
  • Disease management and prognostic purposes
  • Results are positive when >50% of cells are positive for ALK rearrangement
  • Positive for ALK gene rearrangement will qualify for kinase inhibitor drugs
  • Results are negative if <10% of cells are positive
  • A negative result suggests no rearrangement of the ALK gene region at 2p23
  • Results are equivocal when >10% but <50% of cells are positive. If results are equivocal, an additional 50 cells are scored and would be considered positive if >15% of cells exhibit a signal pattern consistent with an ALK rearrangement and negative if <15% of cells exhibit an ALK rearrangement

Negative for ALK gene rearrangement

Fluorescence in situ hybridization (FISH) with breakapart probes of tumor specimens, with useful adjunct of single and multiplex reverse transcription polymerase chain reaction (RT-PCT) assays to detect the wide range of ALK variants.

Formalin fixed paraffin embedded (FFPE) tissue

Stability

  • Fix tissue is stable in room temperature
EGFR, KRAS, p53, LKB1 and PIK3CA mutation analysis, Lung biopsy, Respiratory culture, Viral culture, Acid fast bacilli (AFP) or M. tuberculosis by PCR.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login